GARVINCI

Garvinci is a privately-held Canadian company focused on arthritis and women's health. The Company was founded in 2001 by Jean-Francois Gareau, a Montreal entrepreneur. Garvinci's principal assets are the Canadian distribution rights to a line of ostearthritis products and the Canadian distribution rights to the morning after pill NorLevo® from the French company, Laboratoire HRA Pharma S.A. The osteoarthritis products include a visco-supplement product to relieve the symptomatic pain associ... ated with osteoarthritis of the hip, shoulder and knee. The pipeline also includes an oral interleukin I inhibitor for the symptomatic relief of osteoarthritis which has been on the market in more than 20 countries and for which the Canadian filing for approval is expected in the next 24 months. Garvinci is also in discussions concerning Canadian rights to additional products such as a visco-supplement for smaller joint and a synovial fluid replacement product for relief of pain following arthroscopy. Garvinci has received Notice of Compliance and a DIN number from Health Canada for the HRA Pharma product NorLevo®, a morning-after emergency contraceptive pill, and is currently in discussions with a senior pharmaceutical company to supplement Garvinci's marketing capabilities.More